Pagantangentide

派格安替安吉肽

Report date: 2024/08/08 17:10:04
NME

Base Information

Drug NamePagantangentide
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsRheumatic DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Anji Biological Technology Co LtdJiangsu Aotexin Biomedical Technology Co LtdChina Pharmaceutical University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChina Pharmaceutical UniversityJiangsu Aotexin Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsRheumatic Diseases

Other Information

ATC CodeN/A
Related LinksN/A